Metagenomi Therapeutics (MGX) Free Cash Flow (2023 - 2026)
Metagenomi Therapeutics (MGX) reported Free Cash Flow of -$21.2 million for Q1 2026, up 8.34% year-over-year from -$19.6 million in Q1 2025, and up 11.84% quarter-over-quarter from -$24.0 million in Q4 2025.
Metagenomi Therapeutics (MGX) Free Cash Flow (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has 4 years of Free Cash Flow data on file, last reported at -$21.2 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$21.2 million, up 8.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$87.5 million (up 16.28% YoY), and the FY2025 annual result was -$89.5 million, up 20.25% from the prior year.
- Free Cash Flow improved to -$21.2 million in Q1 2026 per MGX's latest filing, from -$24.0 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$21.0 million in Q2 2025 and troughed at -$30.8 million in Q1 2024.
- A 4-year average of -$24.9 million and a median of -$24.0 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow slumped 30.41% in 2024, then gained 24.82% in 2025.
- A 4-year view of Free Cash Flow shows it stood at -$22.3 million in 2023, then tumbled by 30.41% to -$29.1 million in 2024, then rose by 17.41% to -$24.0 million in 2025, then climbed by 11.84% to -$21.2 million in 2026.
- Business Quant data shows MGX's Free Cash Flow at -$21.2 million in Q1 2026, -$24.0 million in Q4 2025, and -$21.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | 63,220.27 |
| 10 | Metagenomi Therapeutics | 42.84 Mn | 42.84 Mn | - | -21.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.20 Mn |
| Mar 31, 2026 | -21.20 Mn |
| Dec 31, 2025 | -24.05 Mn |
| Dec 31, 2025 | -24.05 Mn |
| Sep 30, 2025 | -21.28 Mn |
| Sep 30, 2025 | -21.28 Mn |
| Jun 30, 2025 | -21.00 Mn |
| Jun 30, 2025 | -21.00 Mn |
| Mar 31, 2025 | -23.13 Mn |
| Mar 31, 2025 | -23.13 Mn |
| Dec 31, 2024 | -29.12 Mn |
| Dec 31, 2024 | -29.12 Mn |
| Sep 30, 2024 | -25.82 Mn |
| Sep 30, 2024 | -25.82 Mn |
| Jun 30, 2024 | -26.48 Mn |
| Jun 30, 2024 | -26.48 Mn |
| Mar 31, 2024 | -30.77 Mn |
| Mar 31, 2024 | -30.77 Mn |
| Dec 31, 2023 | -22.33 Mn |
| Dec 31, 2023 | -22.33 Mn |